Recurrence of metastatic Merkel carcinoma after cessation of avelumab in a patient previously with a complete response

Recurrence of metastatic Merkel carcinoma after cessation of avelumab in a patient previously with a complete response

Abstract Background Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine malignancy. Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with metastatic MCC (mMCC). In mMCC, the response duration after cessation of ICIs treatment for com...

Full description

Bibliographic Details
Main Authors: Alexandra Picard‐Gauci, Laura Troin, Madleen Chassang, Thierry Passeron, Henri Montaudié
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:JEADV Clinical Practice
Online Access:https://doi.org/10.1002/jvc2.3

Similar Items

Similar Items